Survival and progression to AIDS in a seroconverter cohort in the post-highly active antiretroviral therapy era: effectiveness goes on
- 9 January 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 20 (2), 289-291
- https://doi.org/10.1097/01.aids.0000202651.41397.db
Abstract
Progression to AIDS and death for 1129 HIV seroconverters from the GEMES cohort were analysed by calendar period (1996-1997, 1998-1999, 2000 onwards). A further hazard reduction was observed for a later period for both. Intravenous drug users (IDU) had a faster progression. The results highlighted the importance of monitoring the effectiveness of highly active antiretroviral therapy and to improve public health strategies directed to IDU to reduce inequity in HIV infection care.Keywords
This publication has 5 references indexed in Scilit:
- Determinants of survival following HIV-1 seroconversion after the introduction of HAARTThe Lancet, 2003
- Progression to AIDS slowed even more after the first two years with highly active antiretroviral therapyScandinavian Journal of Public Health, 2003
- Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconvertersAIDS, 2003
- Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosisAIDS, 2001
- Effectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in Men With Known HIV Infection DurationJAMA, 1998